Tyra Biosciences Inc
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. It… Read more
Tyra Biosciences Inc (TYRA) - Total Assets
Latest total assets as of September 2025: $301.85 Million USD
Based on the latest financial reports, Tyra Biosciences Inc (TYRA) holds total assets worth $301.85 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Tyra Biosciences Inc - Total Assets Trend (2019–2024)
This chart illustrates how Tyra Biosciences Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Tyra Biosciences Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Tyra Biosciences Inc's total assets of $301.85 Million consist of 95.6% current assets and 4.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 25.3% |
| Accounts Receivable | $2.00 Million | 0.6% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Tyra Biosciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Tyra Biosciences Inc's current assets represent 95.6% of total assets in 2024, an increase from 24.1% in 2019.
- Cash Position: Cash and equivalents constituted 25.3% of total assets in 2024, up from 20.5% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 0.6% of total assets.
Tyra Biosciences Inc Competitors by Total Assets
Key competitors of Tyra Biosciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Tyra Biosciences Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Tyra Biosciences Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Tyra Biosciences Inc is currently not profitable relative to its asset base.
Tyra Biosciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 17.71 | 29.55 | 8.22 |
| Quick Ratio | 17.71 | 29.55 | 8.22 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $265.34 Million | $ 353.24 Million | $ 13.42 Million |
Tyra Biosciences Inc - Advanced Valuation Insights
This section examines the relationship between Tyra Biosciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.32 |
| Latest Market Cap to Assets Ratio | 1.89 |
| Asset Growth Rate (YoY) | 61.0% |
| Total Assets | $363.56 Million |
| Market Capitalization | $687.18 Million USD |
Valuation Analysis
Above Book Valuation: The market values Tyra Biosciences Inc's assets above their book value (1.89 x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Tyra Biosciences Inc's assets grew by 61.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Tyra Biosciences Inc (2019–2024)
The table below shows the annual total assets of Tyra Biosciences Inc from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $363.56 Million | +60.97% |
| 2023-12-31 | $225.86 Million | -15.15% |
| 2022-12-31 | $266.18 Million | -13.21% |
| 2021-12-31 | $306.70 Million | +1815.56% |
| 2020-12-31 | $16.01 Million | +2932.39% |
| 2019-12-31 | $528.00K | -- |